Printer Friendly

NVIDIA® Graphics Power Groundbreaking Cancer-Detection Solution

 
 

NVIDIA Corporation:

Adam Foat Product PR Manager, UK and Northern Europe
NVIDIA Ltd
afoat@nvidia.com
+44 (0)118 903 3019

Press Relations:

James Delves
Wildfire PR
Tel: +44 (0)20 8339 4426
nvidia@wildfirepr.co.uk

FOR IMMEDIATE RELEASE

NVIDIA® Graphics Power Groundbreaking Cancer-Detection Solution

DBT System Developed by Mass General Hospital and Mercury Computer Receives "Imaging Solutions of The Year" Award

THEALE, ENGLAND -FEBRUARY 21, 2006-NVIDIA Corporation (NASDAQ: NVDA) today announced that a groundbreaking cancer-detection system, developed by Massachusetts General Hospital and Mercury Computer Systems, has been recognised by Advanced Imaging Magazine with an "Imaging Solutions of the Year" award. NVIDIA Quadro® FX professional graphics solutions provide the processing power for the computationally-intense system.

Award winners were chosen based on the uniqueness of the challenge as well as on the creativity of their solution. Categories covered the spectrum -- from industrial and machine vision through space imaging and image visualisation to medical, microscopy, military and commercial applications.

Massachusetts General Hospital developed the Digital Breast Tomosynthesis (DBT) imaging system and Mercury Computer Systems developed a high-speed solution to permit rapid processing of the images. NVIDIA Quadro FX includes a unique programmable rendering pipeline that enables the reconstruction of a 3D volume from a series of 2D projection images.

"This award is a significant achievement in our collaboration with Mass General Hospital to improve cancer detection and diagnosis," said Marcelo Lima, vice president of Commercial Imaging and Visualisation at Mercury Computer Systems. "With NVIDIA technology, we hope to take this promising DBT imaging technique from the laboratory to widespread clinical use."

Components of the system also include the Senographe 2000 Digital Mammography System from GE Healthcare and an advanced "likelihood expectation" algorithm co-developed by Brandeis University and Massachusetts General Hospital. The project was supported in part by two grants from the US Army Medical Research and Material Command.

DBT provides the advantage of enabling physicians to "page through" the interior of the breast without obstruction by surrounding superimposed tissue. In the past, the potential benefits of DBT were downplayed because the method was computationally intense and took far too long for use in a clinical setting. With the new system, computation time was reduced from five hours to five minutes, a 60x performance increase. In pre-clinical testing, the new DBT system permitted physicians to find cancers earlier and more easily, and to differentiate benign versus malignant lesions while simultaneously reducing false positives.

Advanced Imaging is dedicated to providing the latest information on imaging hardware, software and peripherals to qualified professionals working with all forms of electronic imaging. For more information on the "Imaging Solutions of the Year" awards, go to: http://www.advancedimagingpro.com/publication/article.jsp?pubId=1&id=2327

About NVIDIA
NVIDIA Corporation is a market leader in visual computing technology dedicated to creating products that enhance the interactive experience on consumer and professional computing platforms. Its graphics and communications processors have broad market reach and are incorporated into a wide variety of computing platforms, including consumer digital-media PCs, enterprise PCs, professional workstations, digital content creation systems, notebook PCs, military navigation systems and video game consoles. NVIDIA is headquartered in Santa Clara, California and employs more than 2,000 people worldwide. For more information, visit the Company’s Web site at www.nvidia.co.uk.

Certain statements in this press release, including any statements relating to the Company's performance expectations for NVIDIA's family of products and expectations of continued revenue growth, are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Such risks and uncertainties include, but are not limited to, manufacturing and other delays relating to new products, difficulties in the fabrication process and dependence of the Company on third-party manufacturers, general industry trends including cyclical trends in the PC and semiconductor industries, the impact of competitive products and pricing alternatives, market acceptance of the Company's new products and the Company's dependence on third-party developers and publishers. Investors are advised to read the Company's Annual Report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, particularly those sections entitled "Certain Business Risks," for a fuller discussion of these and other risks and uncertainties.

# # #

Copyright © 2004 NVIDIA Corporation. All rights reserved. All company and/or product names may be trade names, trademarks and/or registered trademarks of the respective owners with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

Note to editors: If you are interested in viewing additional information on NVIDIA, please visit the NVIDIA Press Room at http://www.nvidia.co.uk/page/press_room.html.



 
 
 
 
FacebookTwitterGoogle+LinkedInPinterest